PDS Biotechnology Corp - Common Stock, par value $0.00033 per share (PDSB)

CUSIP: 70465T107

Q2 2021 13F Holders as of 30 Jun 2021

Holder snapshot 7 signals
Share change
+2,865,875
Put/Call ratio
146%
SEC-reported price per share
$12.55
Number of holders
41
Value change
+$40,638,979
Number of buys
31
Open additional details 1 more signal available
Number of sells
14
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
102,192,638

Security key

70465T107

Report period

Q2 2021

Institutions

41

Top holders

10

Ownership snapshot

Top reported holders of PDSB - PDS Biotechnology Corp - Common Stock, par value $0.00033 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
DeLyle W. Bloomquist
Disclosed value leader
DeLyle W. Bloomquist
Comparable rows
0/15
Latest evidence
16 Jun 2021
3/4/5 13F Highest disclosed value: $7,813,350 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

DeLyle W. Bloomquist has the largest disclosed position value at $7.81M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens DeLyle W. Bloomquist's linked filing trail.
Disclosed position value Top 5
DeLyle W. Bloomquist $7.81M
VANGUARD GROUP INC $3.92M
RENAISSANCE TECHNOLOGIES LLC $3.04M
Ikarian Capital, LLC $1.74M
INSPIRION WEALTH ADVISORS, LLC $1.13M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
DeLyle W. Bloomquist
3/4/5
Resigned as a Director on June 17, 2021.
—
mixed-class rows
$7,813,350
804,941 shares
mixed-class rows
— 16 Jun 2021
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$3,918,000
860,990 shares
— 31 Mar 2021
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$3,038,000
667,747 shares
— 31 Mar 2021
Ikarian Capital, LLC
13F
Company
13F
—
denominator unverified
$1,745,000
383,373 shares
— 31 Mar 2021
INSPIRION WEALTH ADVISORS, LLC
13F
Company
13F
—
denominator unverified
$1,133,000
248,912 shares
— 31 Mar 2021
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$774,000
170,159 shares
— 31 Mar 2021
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
41
Shares
5,941,843
Rows available
41
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2021 vs Q1 2021 Across Filers

Q1 2021 holders
29
Q2 2021 holders
41
Holder diff
12
Investor Q1 2021 Shares Q2 2021 Shares Share Diff Share Chg % Q1 2021 value Q2 2021 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .